89 related articles for article (PubMed ID: 12491207)
1. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.
Yazdanpanah Y; Goldie SJ; Paltiel AD; Losina E; Coudeville L; Weinstein MC; Gerard Y; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
Clin Infect Dis; 2003 Jan; 36(1):86-96. PubMed ID: 12491207
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of HIV post-exposure prophylaxis in France.
Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
[TBL] [Abstract][Full Text] [Related]
4. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
Bayoumi AM; Redelmeier DA
AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
[TBL] [Abstract][Full Text] [Related]
5. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
Scharfstein JA; Paltiel AD; Weinstein MC; Seage GR; Losina E; Craven DE; Freedberg KA
Int J Technol Assess Health Care; 1999; 15(3):531-47. PubMed ID: 10874380
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.
Chung JB; Armstrong K; Schwartz JS; Albert D
Arthritis Rheum; 2000 Aug; 43(8):1841-8. PubMed ID: 10943875
[TBL] [Abstract][Full Text] [Related]
8. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
Sendi PP; Craig BA; Meier G; Pfluger D; Gafni A; Opravil M; Battegay M; Bucher HC
J Antimicrob Chemother; 1999 Dec; 44(6):811-7. PubMed ID: 10590283
[TBL] [Abstract][Full Text] [Related]
10. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.
Yazdanpanah Y; Goldie SJ; Losina E; Weinstein MC; Lebrun T; Paltiel AD; Seage GR; Leblanc G; Ajana F; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
Antivir Ther; 2002 Dec; 7(4):257-66. PubMed ID: 12553480
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
13. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Bachmann MO
AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
18. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS.
Kempen JH; Frick KD; Jabs DA
Pharmacoeconomics; 2001; 19(12):1199-208. PubMed ID: 11772155
[TBL] [Abstract][Full Text] [Related]
19. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
Gona P; Van Dyke RB; Williams PL; Dankner WM; Chernoff MC; Nachman SA; Seage GR
JAMA; 2006 Jul; 296(3):292-300. PubMed ID: 16849662
[TBL] [Abstract][Full Text] [Related]
20. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]